Company profile
Alumis Inc.
NASDAQ: ALMS · Healthcare · Biotechnology
#529 of 1,418 Healthcare companies by revenue
EA Score
35DFH 42DQ 20GM —SS 57
v0.1 · 55/100 weight · provisional
↑ Altman-Z, market scale · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$8.4M
Rev growth YoY (TTM)
-51.7%
Net income (FY)
-$243.3M
Employees
224
as of 2026-08-08
Market cap
$3.4B
as of 2026-08-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$24.1M$24.1M2025
Net income-$243.3M-$243.3M2025
Operating income-$453.8M-$453.8M2025
Total assets$411.9M$411.9M2025
Liabilities$110.6M$110.6M2025
Equity$301.3M$301.3M2025
Revenue by segment
Filed disclosures · FY2025
By product
License72%
Collaboration Revenue28%
By geography
Not disclosed.
The read
What is Alumis Inc.’s revenue?
Alumis Inc. booked $24.1M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -1011.7% net margin.
Peers · Healthcare
Ionic Brands Corp.——Halo Collective Inc.——Precipio, Inc.69BCovalon Technologies Ltd.78B+Wellgistics Health, Inc.19DBody and Mind Inc.——Neighbors
San Mateo →Key facts
CEOMartin Babler
SectorHealthcare
IndustryBiotechnology
HeadquartersSouth San Francisco, CA
ExchangeNASDAQ: ALMS
Employees224
IPO date2024-06-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.